newsfilter
← Latest News
PR Newswire·

Nektar Therapeutics to Participate in Two Investor Conferences in November

  • Nektar Therapeutics (Nasdaq: NKTR) will participate in two investor conferences in London, UK.
  • The company will attend the UBS Global Biopharma Conference with a fireside chat scheduled for Tuesday, November 17, 2026, from 11:20 to 11:50 a.m. GMT.
  • Management will attend the Jefferies Global Healthcare Conference with a fireside chat on Wednesday, November 18, 2026, from 8:00 to 8:25 a.m. GMT.
  • Live \& archived webcasts will be available on the Investor Events section of the Nektar website, with replays accessible for 30 days.
  • Nektar is a clinical-stage biotechnology firm developing treatments for autoimmune \& chronic inflammatory diseases.
  • The lead product candidate rezpegaldesleukin (REZPEG, NKTR-358) is a first-in-class regulatory T cell stimulator being evaluated for atopic dermatitis, alopecia areata, \& Type 1 diabetes.
  • The pipeline includes preclinical bivalent TNFR2 antibody programs NKTR-0165 \& NKTR-0166, \& the modified hematopoietic colony stimulating factor protein NKTR-422.
  • The company is headquartered in San Francisco, California.
Company
Nektar Therapeutics
Keywords
Nektar Therapeutics